Susan Podlogar left the role of Director at Tevogen Inc. As of November 6, 2026, Tevogen Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 16, 2026 to November 4, 2026, naming 1 departure (Form 8-K, November 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Tevogen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Susan Podlogar · Role: Director · 8-K, 2026-11-04
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-03
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-16
Tevogen Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-16 to 2026-11-04. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Tevogen Inc. files it.
Also on the record for Tevogen Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Stake report, Schedule 13D/A, by Saadi Ryan H. | 91.1% of the class | 5%+ stakes | Source |
| September 16, 2026 | Stake report, Schedule 13D/A, by Kirti Desai | 6.3% of the class | 5%+ stakes | Source |
| September 16, 2026 | Stake report, Schedule 13D/A, by Saadi Ryan H. | 74.4% of the class | 5%+ stakes | Source |
| July 14, 2026 | Stake report, Schedule 13D/A, by Saadi Ryan H. | 59.7% of the class | 5%+ stakes | Source |
| December 16, 2025 | Stake report, Schedule 13D/A, by Ryan H. Saadi | 62% of the class | 5%+ stakes | Source |
| July 25, 2025 | Stake report, Schedule 13D/A, by Ryan H. Saadi | 64.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Tevogen Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tevogen Inc. and the records around it.
Tevogen Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Watch Tevogen Inc.
Get an email when Tevogen Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tevogen Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Tevogen Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tevogen Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | Out | Director | 8-K, 2026-11-04 | ||
| 2026-11-03 | Reported | not named in the filing | 8-K, 2026-11-03 | ||
| 2026-09-16 | Reported | not named in the filing | 8-K, 2026-09-16 |
Who leads Tevogen Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Susan Podlogar, departure reported (filed 2026-11-04). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Tevogen Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Tevogen Inc., with the record behind each one.
Find candidates like Director at Tevogen Inc.Every change, in the filing's words
Departing: Susan Podlogar, Director
On November 2, 2026, Susan Podlogar gave notice of her resignation from service as a director of Tevogen Inc. (the "Company"), effective immediately.
- In connection with Ms. Podlogar's resignation, the Company's Board of Directors (the "Board") approved a reduction in the size of the Board from six to five directors and appointed current director Lindee Goh to serve as a member of the Audit Committee, in each case effective November 2, 2026.
Reported
Termination of Service : In the event Dr. Saadi's Service terminates for any reason prior to vesting, the Restricted Shares will be forfeited.
- Restricted Stock Award On November 2, 2026 (the "Grant Date"), Tevogen Inc. (the "Company") granted Ryan Saadi, Chief Executive Officer and Chairperson of the Company's Board of Directors (the "Board"), a restricted stock award (the "RSA") under the Tevogen Inc. 2024 Omnibus Incentive Plan (the "Plan"), covering 50,000,000 shares ("Restricted Shares") of the Company's common stock, par value $0.0001 per share ("Common Stock").
- The Restricted Shares will vest only upon the Board's certification of the Company's achievement of $1.0 billion in aggregate revenue by December 31, 2031 (the "Revenue Threshold") and satisfaction of the other applicable vesting conditions.
- Prior to vesting, Dr. Saadi will have the right to vote the Restricted Shares, but they will remain subject to the transfer restrictions and substantial forfeiture conditions described below.
- Following the grant and repayment under the Loan Agreement on November 2, 2026, Dr. Saadi held approximately 90.9% of the voting power represented by the 67,880,267 shares of outstanding Common Stock.
- Background In approving the RSA, the Board considered, among other things, the Company's long-term growth and acquisition strategy and the importance of retaining and incentivizing Dr. Saadi.
Reported
Termination of Service : In the event the grantee's Service terminates for any reason prior to vesting.
- Vesting of the Restricted Shares is subject to the Board's certification of the Company's achievement of $1.0 billion in aggregate revenue by September 30, 2031 (the "Revenue Threshold"), and the Restricted Shares may not be sold, transferred by gift, pledged, hypothecated, or otherwise transferred or disposed of prior to vesting.
- Each grantee will have the right to vote the Restricted Shares prior to vesting.
- As of immediately following the grant on September 14, 2026, Dr. Saadi directly or indirectly owned 74.4% and Mr. Desai directly owned 6.3% of the 15,736,540 shares of outstanding Common Stock.
- Background The RSAs are intended to align Dr. Saadi's and Mr. Desai's realized compensation with the Company's growth and success by making vesting contingent on achievement of the Revenue Threshold.
- The Board believes that the executives' continued leadership is instrumental to the Company's progress and that retaining and incentivizing Dr. Saadi and Mr. Desai through equity grants and providing each of them a continued important say in the Company's future through the voting rights incident to the Restricted Shares is in the best interests of the Company and its stockholders.
Tools for this story
Each opens in a new tab, filled in for Tevogen Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.